Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
APOBEC1 complementation factor
(
A1CF
) is a component of the apolipoprotein-B messenger RNA editing complex that participates in various cellular processes and acts as an oncogene in many cancers. In this study, it was aimed to investigate the roles of
A1CF
and its potential mechanism in
endometrial cancer
(EC).
Materials and Methods:
Gene expression prolife was downloaded from The Cancer Genome Atlas database. Then Kaplan-Meier and Cox regression analyses were conducted to assess the prognostic value of
A1CF
in EC. Cell Counting Kit-8, plate clone formation, and transwell assays were used to estimate the functions of
A1CF
on the proliferation, invasion, and migration of EC cell. The gene set enrichment analysis was used to analyze the pathway that is enriched by
A1CF
, whereas quantitative real-time polymerase chain reaction and Western blot analyses were utilized to detect the mRNA and protein expression involved.
Results:
It was detected that the upregulated
A1CF
was enriched in P53/P21 signaling pathway and tightly associated with patients' age, stage, and death. Besides, high
A1CF
expression led to a shorter overall survival of patients and predicted a poor prognosis in EC. The overexpression of
A1CF
promoted the proliferation, invasion, and migration of EC cells, whereas the depletion of
A1CF
suppressed these processes. Moreover, P21 and P53 were reduced whereas cyclin D1 and proliferating cell nuclear antigen were induced along with the increasing of
A1CF
. However, the effects of silencing
A1CF
on these protein expressions were on the contrary.
Conclusion:
A1CF
was highly expressed and closely related to the prognosis and progression of EC through the regulation of P53/P21 signaling pathway, providing a possible new therapy target site for EC.
...
PMID:High APOBEC1 Complementation Factor Expression Positively Modulates the Proliferation, Invasion, and Migration of Endometrial Cancer Cells Through Regulating P53/P21 Signaling Pathway. 3281 82
